AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00446758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children > 12 months.
Study NCT00446758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children > 12 months.
Study NCT04149847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inguinal hernia repair
Description: patients 18 years and above presenting with primary inguinal hernia
Study NCT00857584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Flexible dose from 50 to 200 mg/d (combination of tablets of 50mg and 100mg) oral, daily, 8 weeks length.~Sertraline titration: 50 mg on day 1-3, 100 mg on day 4, and flexible doses of 50 to 200 mg/d from day 5 to the end of the study.
Study NCT00857584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adequate mood stabilizer
Description: An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
Study NCT01357889 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide (GSK716155)
Description: subcutaneous injection administered once a week
Study NCT03454204 — intervention group
Intervention type: OTHER
Intervention: Pharmacokinetic
Description: Analysis of blood samples
Study NCT04402619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: The ten modules cover:~* Psychoeducation about sleep, sleep problems, and associations with alcohol~* How to keep and use a sleep diary~* Sleep hygiene~* Sleep compression~* Cognitive restructuring~* Emotional regulation~* Preparing for the future
Study NCT00054236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1
Study NCT00054236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
Study NCT00054236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide IV over 2 hours on days -3 to -2
Study NCT00054236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: fludarabine IV over 30 minutes on days -8 to -4
Study NCT00054236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.
Study NCT00054236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
Study NCT00857584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adequate mood stabilizer
Description: An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
Study NCT06489457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide subcutaneous injection once weekly titrated to 1 mg in concordance with Summary of product characteristics (SmPC) (0.25 mg once weekly in the first month, 0.5 mg once weekly in the second month and 1 mg once weekly from the third month onward)
Study NCT05729269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sarcopenia_CT
Description: measurement of skeletal muscle through abdominal computed tomography
Study NCT01040845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone/Ethinyl Estradiol
Description: one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
Study NCT06489457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Undecanoate
Description: Testosterone Undecanoate intramuscular injection 1000 mg once per 10-12 weeks
Study NCT02774096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xenon
Study NCT04642937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with hP1A8
Description: Treatment with hP1A8
Study NCT02838810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa
Description: peginterferon alfa-2b or peginterferon alfa-2a
Study NCT02838810 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nucleoside analogues
Description: Nucleoside analogues
Study NCT02737332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zytiga® (Abiraterone Acetate)
Description: Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart
Study NCT02737332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoluMatrix™ (Abiraterone Acetate)
Description: SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
Study NCT00475150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT00475150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03102801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin S
Description: Humulin S used to induce hypoglycaemia
Study NCT00432302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY 86-5302, ZK 219477)
Description: First infusion only: 28 mg, containing 14 kBq/7.8 mcg \[14C\]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
Study NCT03512418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEPsteps
Description: Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT).
Study NCT03512418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital pill
Description: The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.
Study NCT03512418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital pill
Description: The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.
Study NCT03512418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: Participants receive once daily Truvada as PrEP to prevent HIV.
Study NCT03512418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Participants receive once daily Truvada as PrEP to prevent HIV.
Study NCT02177656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing tailored intervention
Description: MI is grounded in client-centered counseling, cognitive-behavioral therapy, and social cognitive therapy. MI integrates the concepts of relationship building from humanistic therapy with active strategies oriented towards stages of change.The main characteristics of motivational interviewing are: expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. The interviewer maintains a nonjudgmental approach and allows the patient to determine the need for behavioral change, rather than offering unsolicited advice on the need for change. The interviewer only explores ways to implement change once the patient expresses the desire and confidence to change. The goal of MI is to help individuals work through inherent ambivalence present in problematic or unhealthy behaviors and to help them verbally express reasons for or against change using a nonjudgmental, empathetic and encouraging tone.
Study NCT03261960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4700
Description: Oral bowel preparation
Study NCT01040845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norethindrone/Ethinyl Estradiol
Description: one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
Study NCT00912782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one time per week for 3 weeks
Study NCT01861665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine- 0.25%
Description: Marcaine 0.25% administered pre-incision.
Study NCT03261960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium bowel preparation
Description: Oral bowel preparation
Study NCT01752686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin as adjuvant chemotherapy
Study NCT00045669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT01861665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.25%.
Description: Marcaine 0.25% administered post-incision.
Study NCT03121144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Centroid System
Description: Noninvasive positional monitoring device
Study NCT01040845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6mg tablet every 12 hours on Days 8 to 21
Study NCT03928041 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Device: EVOS Lumbar Interbody System (EVOS-HA)
Description: All subjects will receive the EVOS Lumbar Interbody System (EVOS-HA) device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease and spondylolisthesis.
Study NCT01040845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: 0.6mg tablet every 12 hours on Days 8 to 21
Study NCT01040845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Colchicine)
Description: placebo tablet every 12 hours on Days 8 to 21
Study NCT03121378 — intervention group
Intervention type: OTHER
Intervention: Blood sample 1
Description: Blood taken before prosthesis implantation
Study NCT03121378 — intervention group
Intervention type: OTHER
Intervention: Blood sample 2
Description: Blood taken after prosthesis implantation
Study NCT02431182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Training Workshop
Description: 1. Presentation of the workshop: Objectives and Methodology~2. Explanation of the different types of memory and its implication in normal life~3. Strategies for gathering and codification of the information~4. Strategies for selection and storage the information~5. Strategies for gathering, codification, selection, storage and recuperation of the information. Importance of the context and the meaning of things. Semantic and episodic memory~6. Strategies for gathering, codification, selection, storage and recuperation of the information. Individual differences~7. Strategies for recuperation according to the individual profile. Improving self-esteem~8. Strategies for recuperation Social skills.~9. Personal and social skills~10. New contexts and opportunities~11. Evaluation of the workshop
Study NCT03180112 — intervention group
Intervention type: GENETIC
Intervention: enzyme linked immunosorbent assay and polymerase chain reaction
Description: Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
Study NCT04271358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Health Coaching
Description: The Peer Coaching group will receive 6 months of peer health coaching via a secure telephone and text messaging system.
Study NCT01427218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titration of medications
Description: Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).
Study NCT01427218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity
Study NCT01427218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Counseling
Description: The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.
Study NCT01427218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care with Medication Reconciliation
Description: A medication history and assessment of adherence will be completed by the pharmacist.
Study NCT01761708 — intervention group
Intervention type: PROCEDURE
Intervention: primary ventral hernia repair with mesh
Study NCT04389905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dental education - Motivational Interviewing
Description: Motivational Interviewing - Focusing on oral/dental health
Study NCT02336815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
Study NCT02336815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg was given with each dose of Selinexor.
Study NCT02002507 — intervention group
Intervention type: OTHER
Intervention: comparison of different neurosurgical position
Description: in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
Study NCT01333722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended Release
Study NCT01040845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Colchicine)
Description: placebo tablet every 12 hours on Days 8 to 21
Study NCT00086736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Study NCT01333722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT00003846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00086736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eflornithine
Study NCT00086736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral eflornithine placebo
Study NCT00086736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral bicalutamide placebo
Study NCT00649168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
Description: 2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Study NCT00003846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Study NCT00003846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00003846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Study NCT00472862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
Study NCT00472862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
Study NCT00003846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00003846 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02829996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabodenoson 6.0% / latanoprost 0.005% QD
Description: Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
Study NCT02829996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabodenoson 3.0% / latanoprost 0.005% QD
Description: Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
Study NCT02829996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabodenoson 6.0% / latanoprost 0.0025% QD
Description: Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
Study NCT02829996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% QD
Description: Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
Study NCT02829996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.0025% QD
Description: Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
Study NCT00649168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
Description: 2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Study NCT00961116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid (Fibricor™) 105 mg Tablet
Description: 1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours
Study NCT00961116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate (Tricor®) 145 mg Tablet
Description: 1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
Study NCT01459770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Information Transfer Intervention
Description: A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
Study NCT01459770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for hospital discharge
Description: Patients will receive medication information according to standard practice for discharge of hospitalized patients.
Study NCT00389441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
Study NCT03530150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone Oral Product
Description: A pill containing 600 mg of pirfenidone
Study NCT02309814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eyelid motion sensor device (Hall-probe)
Description: all volunteers will wear the eyelid motion sensor device (Hall-probe) (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance
Study NCT02124941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: Upon completion of baseline (abstinence) 1H-MRS scanning, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
Study NCT02124941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]FDG PET scan
Description: All subjects will undergo \[18F\]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
Study NCT04120129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Transcranial Magnetic Stimulation (TMS) is a noninvasive brain stimulation technique which produces short pulsatile magnetic fields (similar to that of an MRI) via two extracranial, figure 8-shaped electric coils which can induce a small, temporary, electric current in the brain currently approved and used for depression.